HAL (France)open access
Impact of first-line immunotherapy on survival and intracranial outcomes from a real-world cohort of patients with non-small cell lung cancer with brain metastases at diagnosis.
Brain metastases, 0, Intracranial therapy, Non-small-cell lung cancer, Immune checkpoint inhibitor, Stereotactic raduisrugery
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 676991
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.